Neurofibromatosis Type 2
Last Posted: Jul 14, 2021
- Increased risk for dementia in neurofibromatosis type 1
RA Kalionpaa et al, Genetics in Medicine, July 13, 2021
- Effects of a mind-body program on symptoms of depression and perceived stress among adults with neurofibromatosis type 2 who are deaf: A live-video randomized controlled trial.
Carter Sarah et al. Complementary therapies in medicine 2020 Oct 56102581
- Neurofibromatosis type 2 in Phelan-McDermid syndrome: Institutional experience and review of the literature.
Ziats Catherine A et al. European journal of medical genetics 2020 Aug 104042
- Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.
Pemov Alexander et al. Scientific reports 2020 Jul 10(1) 12563
- Inherited genetic syndromes and meningiomas.
Look Andrew et al. Handbook of clinical neurology 2020 169121-129
- Encouraging News for Kids with Neurofibromatosis Type 1
NIH Director's Blog, March 24, 2020
- Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Louvrier Camille et al. Neuro-oncology 2018 20(7) 917-929
- CLINGEN Actionability Report for Neurofibromatosis Type II -NF2
ClinGen Actionability Working Group
- FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment
NCI Cancer Research, May 2018
- First report of the efficacy of vestibular rehabilitation in improving function in patients with Neurofibromatosis type 2: an observational cohort study in a clinical setting.
Emmanouil Beatrice et al. Disability and rehabilitation 2018 Mar 1-7
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Graves Disease
- Huntington Disease
- Myasthenia Gravis
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.